Nanoparticles-based anti-aging treatment of Alzheimer’s disease

Jian-Jian Chu, Wen-Bo Ji, Jian-Hua Zhuang, Bao-Feng Gong, Xiao-Han Chen, Wen-Bin Cheng, Wen-Danqi Liang, Gen-Ru Li, Jie Gao and You YIN

ABSTRACT
Age is the strongest risk factor for Alzheimer’s disease (AD). In recent years, the relationship between aging and AD has been widely studied, with anti-aging therapeutics as the treatment for AD being one of the mainstream research directions. Therapeutics targeting senescent cells have shown improvement in AD symptoms and cerebral pathological changes, suggesting that anti-aging strategies may be a promising alternative for AD treatment. Nanoparticles represent an excellent approach for efficiently crossing the blood-brain barrier (BBB) to achieve better curative function and fewer side effects. Thereby, nanoparticles-based anti-aging treatment may exert potent anti-AD therapeutic efficacy. This review discusses the relationship between aging and AD and the application and prospect of anti-aging strategies and nanoparticle-based therapeutics in treating AD.

1. Introduction
AD is the most common form of dementia, accounting for about 60–80% of all dementia cases (Alzheimer’s Association, 2021). AD can lead to impaired cognitive functions such as memory, language, and learning, the decline of executive function, and mental symptoms. Age is one of the strongest risk factors for AD (Hebert et al., 2010). In China, 18.70% of the population is more than 60 years of age (Communiqué of the Seventh National Population Census). More than one-fifth of this population suffers from mild cognitive impairment (MCI) and dementia, and 3.9% is the case rate of AD (Jia et al., 2020). With the aging population, many AD patients and those suffering from dementia and MCI will become a heavy health and economic burden for individuals, families, and societies all over the world in the foreseeable future (Jia et al., 2020; Alzheimer’s Association, 2021). Hence, many studies have focused on the treatment of AD.

Based on the cholinergic hypothesis and excitotoxicity hypothesis, the commonly used drugs for the treatment of AD include acetylcholinesterase inhibitors and noncompetitive N-methyl-D-aspartic acid (NMDA) receptor antagonists, which show moderate improvement in symptoms (Livingston et al., 2020) but do not delay or stall the damage and destruction of neurons (Alzheimer’s Association, 2021). Currently, the disease-modifying treatments (DMTs) for AD are urgently needed. According to the prevailing viewpoints, β-amyloid (Aβ) deposition and the abnormal hyperphosphorylation of tau proteins serve as the main pathogenesis and pathological features of AD (Bloom, 2014; Sengupta et al., 2016). Targeting Aβ protein has always been one of the cores of AD research and treatment development (Nalivaeva & Turner, 2019). Compared with Aβ, cognitive impairment and neuron loss are closely correlated with abnormal hyperphosphorylation of tau protein (Nelson et al., 2012). Strategies for targeting tau protein are always the research hotspots. Nevertheless, there are still no significantly effective DMTs for AD until now.

Due to the distinctiveness of the age of onset of AD, aging has always been closely related to the disease. Aging can be defined as the decrease in the psychological and physiological adaptability of the body to the environment, eventually leading to death. One of the features of aging is the accumulation of senescent cells in many tissues (Campisi, 2011). In addition to the decline of normal functions, the other causes of senescence leading to aging-related diseases are also associated with the secretion of senescence-related secretory phenotype (SASP) from senescent cells, which induce the damage of the adjacent cells and change the microenvironment around them (Childs et al., 2015). Senescent cells of the cerebrum, especially senescent astrocyte and senescent microglia, play an important role in the development and progression of AD and have been studied widely. Although the exact mechanism of senescence cells and AD has not been well expounded, anti-aging strategies have exhibited great potential and can become an effective treatment avenue for AD (Kritsillis et al., 2018).

CONTACT You YIN yinyou179@163.com Department of Neurology, Second Affiliated Hospital (Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China; Jie Gao jmsx2021@shu.edu.cn Changhai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China.

#These authors contributed equally.
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The BBB hinders the entry of many agents into the CNS, including most anti-aging drugs. There are many strategies to increase the stability and efficiency of anti-senescent drugs and lower their loss while penetrating BBB, and one of the promising choices is nanoparticles. Nanoparticles can be of different types (e.g. lipid-based NPs, polymeric NPs, inorganic NPs, and nanogels) and can assist drugs in entering the CNS by bypassing or directly passing through the BBB. In this review, we mainly discuss nanoparticles that directly penetrate the BBB. They can cross over the BBB by four main pathways, including carrier-mediated transport (CMT), receptor-mediated transcytosis (RMT), adsorptive-mediated transcytosis (AMT), and cell-mediated transport (Furtado et al., 2018; Bilal et al., 2020).

2. Aging and AD

The nervous system is a dynamically balanced integration of a wide range of functional cells. Typically, most neurodegenerative diseases are manifested in the elderly (Grimm & Eckert, 2017). Aging is the most important risk factor for the development of neurodegenerative diseases. The incidence rate of AD has increased with increasing age (Jia et al., 2020). The primary mechanism by which aging promotes the process of AD may be attributed to the abnormal functioning of senescent cells and the persistent chronic inflammation in the CNS induced by the active secretion of SASP by senescent cells ( Franceschi & Campisi, 2014; Heneka et al., 2015; Birch & Gil, 2020), which finally results in decreased synaptic function or neuron loss. However, the causal relationship between aging and AD is not clear. In this review, we search for the clues of aging in AD from three aspects: aging glial cells, aging neurons and neural stem cells, and aging BBB.

2.1. Aging glial cells

Several studies have focused on the senescence of microglia, astrocytes, oligodendroglia, and oligodendrocyte progenitor cells (OPCs) for their crucial roles in neuroprotection, and maintenance of CNS homeostasis (ion concentration, neurotransmitters, inflammatory mediator, etc.), and the brain immune system (Jessen, 2004).

Microglia are the primary immune cells in CNS and are usually in a static state. They are similar to macrophages in function, secrete various growth factors and cytokines, and stimulate phagocytosis in response to invasive pathogens or damage (Nayak et al., 2014). Microglia play critical roles in maintaining CNS homeostasis by clearing misfolded proteins and controlling inflammation (Mhatre et al., 2015). They can accumulate around Aβ deposits and then phagocytize and clear Aβ (Yeh et al., 2016). Human genetic studies have identified microglia as a key cell type to control the risk of AD. Genetic risk variants of AD such as APOE4, TREM2, CD33, ABCA7, HLA-DRB1/85, and INPP5D were identified as moderately or highly expressing in microglia via human genome-wide association studies (GWAS) (Mhatre et al., 2015). Senescent microglial cells have been discovered to express aging-related phenotypes. Treatment of BV2 microglia with lipopolysaccharide resulted in growth arrest, SA-β-Gal up-regulation, and senescence-associated heterochromatin foci (SAHF) (Yu et al., 2012). In another study, microglia from aged mice exhibited increased production of the pro-inflammatory cytokines such as IL-6, IL-1β and TNF-α (Sierra et al., 2007), which were identified as the characteristics of senescent cells. Senescent microglia positive for p16Ink4a was found to accumulate in mice model of tau-dependent neurodegenerative disease, and their disruption greatly reduced the observed pathology (Krishnamurthy et al., 2004; Bussian et al., 2018). In AD patients, the human Alzheimer’s microglia (HAM) profile analysis reflected an enhanced human aging phenotype and unique transcriptional activation (Srinivasan et al., 2020).

Astrocytes are one of the most abundant cell types in the brain. They are responsible for homeostatic maintenance at all levels of the organization, from the molecular to the whole organ in the CNS (Verkhatsky & Nedergaard, 2018). Astrocytes exposed to various stresses lead to aging, which is characterized by the SA-β-Gal activity, growth arrest, increased expression of p16, p21, and p53, and SASP production (Bitto et al., 2010). With the increase in age, the number of p16Ink4a positive astrocytes increases in human brain tissue (Bhat et al., 2012). Senescent astrocytes expressing SASP were enriched in the frontal cortex of patients with AD as compared to age-matched non-AD adults (Bitto et al., 2010). Genes related to neuronal development and differentiation were down-regulated in senescent astrocytes, while pro-inflammatory cytokines genes were upregulated (Boisvert et al., 2018). Meanwhile, senescent astrocytes increased the vulnerability of neurons to glutamate toxicity (Limbad et al., 2020), which is also one of the hypotheses of AD pathogenesis and the reason for cellular senescence.

In the CNS, myelin is an extension of oligodendrocytes concentrically wrapped around nerve axons (Kuhn et al., 2019). Functionally, myelin facilitates rapid transmission of axonal potentials and provides metabolic support to wrapped nerve axons. They are highly vulnerable to oxidative stress (Giacci et al., 2018). White matter changes in AD are thought to reflect both demyelination and axonal damage (Prins & Scheltens, 2015), while SA-β-Gal upregulation of oligodendrocyte in human cerebral tissue of white matter lesion (WML) may be evidence of oligodendrocyte senescence in AD (Al-Mashhadi et al., 2015). In the brains of human patients with AD and APP/PS1 mice model, OPCs with high expression of senescent phenotypes (p21, p16, and SA-β-Gal) were correlated with amyloid plaques, whereas in age-matched subjects without dementia, these senescent phenotypes were not obvious (Zhang et al., 2019). OPCs are very important for myelin regeneration following injury (Kuhn et al., 2019). Young mice had highly active myelin metabolism, while in aged mice, it was greatly inhibited, which coincides with spatial memory deficits (Wang et al., 2020). The impaired function of senescent OPCs may play a crucial role in disease progression, and reduced self-healing capacity could be due to the aging process and pathological factors such as Aβ deposition or NFT (Cai & Xiao, 2016; Zhang et al., 2019).
2.2. Aging neurons and neural stem cells (NSCs)

We can deduce from the relationship between age and AD that the function of neurons declines with age. In AD, the rate of human hippocampal neurogenesis slows, and many hippocampal neurons are lost. It was previously thought that aging only occurred in mitotic cells and that neurons are post-mitotic cells that do not experience cell senescence (Ishikawa & Ishikawa, 2020). This concept has changed in the last decade. An experiment conducted in 2012 proved that compared with the neurons in young mice, the aging phenotypes (SA-β-gal, p38MAPK, and IL-6) of neurons in old mice were greatly increased (Jurk et al., 2012). When in vitro primary rat hippocampal neurons were treated with AraC—a DNA intercalator—for 28 days, SA-β-gal activity increased, and p16 was upregulated (Ishikawa & Ishikawa, 2020). Other experiments also provided evidence of neural senescence, such as rising topoisomerase Iβ, SA-β-gal, and reactive oxygen species (ROS) (Bhanu et al., 2010; Geng et al., 2010; Dong et al., 2011). More evidence of senescent neurons and senescent NSCs in AD is being discovered. Data from the dentate gyrus of APP/PS1 transgenic mouse model of AD showed upregulated p16 and increased SA-β-gal positive neural stem/progenitor cells (NSPCs) (He et al., 2013). Moreover, the number of NSCs in the brain of aging mice was observed to decrease sharply (Shook et al., 2012), and the activated capacity of quiescent neural stem cells (qNSCs) decreased with increasing age (Xie et al., 2020).

2.3. Aging BBB

BBB regulates the material exchange between blood and cerebral parenchyma, thereby maintaining the homeostasis of CNS. BBB mainly comprises brain capillary endothelial cells (BCECs), astrocytes, and pericytes. Among these, capillary endothelial cells play a major role in maintaining the integrity of BBB (Daneman & Prat, 2015). The integrity breakdown and increased permeability of BBB were observed in normal elderly, especially those with AD. This is conducive to the entry of peripheral toxic or inflammatory factors into the CNS. Compared with normal control groups, dynamic contrast-enhanced magnetic resonance imaging could detect significantly higher levels of gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in cerebrospinal fluid (CSF) after injection in AD cases (Yamazaki & Kanekiyo, 2017). The increase in blood-derived molecules and CSF/blood albumin ratio in the CNS of AD patients also verified this observation. Another review indicated reduced capillary density in the brain of aging and AD, which decreases the supply of essential nutrients and clearance of Aβ (Yamazaki & Kanekiyo, 2017). Impaired capillary endothelial cells may be the primary cause of dysfunctional BBB in AD, which can partly be attributed to cellular senescence. Some in vitro and in vivo modeling studies have indicated that senescent microvascular endothelial cells express a significant rise in SA-β-gal activity and p16INK4a and p21 levels and are accompanied by the destruction of BBB integrity (Brown & Thore, 2011). There are few studies on senescent cells in BBB of neurodegenerative diseases, and more studies are expected to clarify the role of senescent capillary endothelial cells and other composing cellular senescence in BBB dysfunction. In this review, we have attributed the dysfunctional BBB to cellular senescence as aging BBB.

Not much is known about the causal relationship between senescent cells and AD, but every type of senescent cell in the CNS and their interaction may be involved in AD pathogenesis. They constitute a complex interactive network (Figure 1) and finally lead to the degeneration and loss of normal neurons, leading to the onset and progression of AD. Future studies are expected to seek specific aging hallmarks and elucidate the interaction of different types of senescent cells in the cerebral of AD.

3. Anti-aging as therapeutics for AD

At present, there are no therapies to effectively change the course of AD and prevent the disease progression. Although aducanumab—a kind of amyloid monoclonal antibody—has been approved by the Food and Drug Administration in June 2021 (Aducanumab, 2012), controversy persists because relevant analyses did not prove the efficacy and safety of aducanumab in improving the disease (Alexander et al., 2021; Knopman et al., 2021). Targeting Aβ agents conducted in preclinical, early, and late stages of AD did not show abundant clinical efficacy (Vaz & Silvestre, 2020). Besides targeting Aβ, tau-aimed treatments have received more attention in the last years; however, most anti-tau drugs were still in the early phase of clinical trials (Vaz & Silvestre, 2020). Many lines of evidence implicate that cellular senescence plays an important role in the pathogenesis of AD, so anti-aging treatment can be another option for DMTs.

3.1. Senolytics-based senescent cells clearance

The elimination of senescent cells has shown improvement in many age-related diseases such as renal dysfunction, idiopathic pulmonary fibrosis, nonalcoholic fatty liver disease, osteoarthritis, a decline in immune function with age, cardiovascular disease, sarcopenia, and so on (Baker et al., 2011; McHugh & Gil, 2018). The effort to find senolytics started in 2005 and more than a dozen kinds of senolytic drugs (Table 1) have been identified by targeting senescent cells’ anti-apoptotic pathway to induce apoptosis in senescent cells (Prata et al., 2018; Kirkland & Tchkonia, 2020).

The removal of senescent cells has been shown to improve pathology or symptoms in Alzheimer’s disease patients and experimental models. A tau-dependent neurodegenerative disease mouse model was used in the study, which accumulated p16INK4a positive senescent astrocytes and microglia (Bussian et al., 2018). In these mice, genetic methods (INK-ATTAC transgene and AP20187 administered) and senolytic ABT263 (navitoclax) were used to remove senescent astrocytes and microglia could prevent gliosis, hyperphosphorylation of soluble and insoluble tau, and degeneration of neurons in the cerebral cortex and hippocampus (Bussian et al., 2018).
Similarly, other senolytics compounds—dasatinib and quercetin (D + Q)—applied for the intermittent treatment lasting up to three months to clear senescent cells associated with tau aggregation, significantly alleviated pathological characteristics, including the number of cortical neurons containing NFTs, ventricular pathological enlargement, and brain cortical atrophy (Musi et al., 2018). However, that study did not observe improvement in cognitive-related symptoms by clearing senescent cells in the mice model and is expected to be verified in later studies. Different from tau dependent model, D + Q removed senescent OPCs that highly expressed p16 induced by Aβ in short-term treated APP/PS1 mutant AD mice, reduced neuroinflammation and Aβ plaque size, and in the long-term intermittent treatment, it alleviated learning and memory deficits (Zhang et al., 2019). D + Q, as the most representative senolytics, could recruit phase II pilot (NCT04063124) volunteers to determine this drug effect in human patients by monitoring tau protein, amyloid, IL-6, and

Reference annotations:
*doi:10.1002/alz.12328, *doi:10.1038/nm.4000, **doi:10.1002/adma.201801362, ***doi:10.1111/joim.13141, ****doi:10.1002/advs.202004929, †doi:10.1101/gad.343129.120, ‡doi:10.1056/NEJMra0912273.

Nanoparticles-based anti-aging treatment is a promising therapeutics for AD.
p16 level in the CSF and action and cognitive tests. To our knowledge, except for navitoclax and D+Q, other senolytics are not yet in use in AD models in vivo or in vitro. However, existing experiments have proved that senolytic drugs, which can selectively target senescent cells more than healthy cells, are effective pathogenesis-based DMTs modality for AD. Studies have focused on finding new therapeutic targets for senescent cells and developing pertinent therapeutic agents. Recently, urokinase plasminogen activator receptor (uPAR) was identified as a protein widely induced on the surface of senescent cells and showed that chimeric antigen receptor (CAR)T cells targeting uPAR could effectively and safely eliminate senescent cells around liver fibrosis (Amor et al., 2020).

Limited studies of anti-aging therapeutics have demonstrated great potential for treating AD, but they are still far from clinical application.

### 3.2. Autophagy-base strategies

Autophagy is an important lysosomal degradation pathway mediated by several autophagy-related (ATG) genes, stabilizing cytoplasmic components, including degraded, misfolded, or aggregated proteins and damaged organelles promote the maintenance of cellular homeostasis (Glick et al., 2010). Autophagy capacity and ATG gene expression and protein levels decrease with age; genetic experiments of various model organisms have revealed that aging is directly related to different ATGs, and overexpression of a single ATG gene has been shown to prolong the life span of neurons (Hansen et al., 2018). The aging rodent brain showed notably increased mammalian target of rapamycin (mTOR)C1 activity and overall decreased ATG protein levels (Ott et al., 2016). In addition, down-regulation of ATG genes, including atg-5, atg-7, and becn-1 has also been observed in the aging human brain (Lipinski et al., 2010), indicating decreased autophagy. Similarly, mice with deficient ATG genes showed spontaneous and accelerated neurodegeneration and massive neuronal loss in the CNS cortex (Hara et al., 2006; Komatsu et al., 2006). Another report indicated that, except for neurons, autophagy of glial cells plays a critical role in the clearance of Aβ (Ries & Sastre, 2016), which can explain how impaired autophagy of glial cells affects the survival of nearby cerebral cells and induces the senescence and dysfunction of adjacent neurons. Thus, the decline in autophagy function, subsequent decrease in protein homeostasis, and increased protein toxicity over time are usually considered to contribute significantly to the development or progression of diseases, including neurodegenerative diseases. Autophagy may be reduced in AD and promote the accumulation of intracellular and extracellular Aβ (Pickford et al., 2008). The dysfunction of the lysosomal autophagy system was found to help the formation of tau oligomers and insoluble aggregates (Hamano et al., 2008). In contrast, stimulation of autophagy eased neurodegeneration owing to Aβ accumulation and Tau denaturation (Watanabe et al., 2020). Reducing mTOR levels and signaling by removing one copy of the mTOR gene led to increased induction of autophagy and improvement in AD-like changes, including cognition and pathological defects (Caccamo et al., 2014). Therefore, the restoration or promotion of autophagy function has been proposed as a promising method for delaying age-related diseases, including AD. Potential strategies included pharmacological treatments using mTORC1 inhibitors (rapamycin (Kaeberlein & Galvan, 2019), rapamycin analogs (Fanoudi et al., 2018), memantine (Son et al., 2016), latrepirdine (Steele & Gandy, 2013), and resveratrol (Kou & Chen, 2017), activating AMPK (resveratrol (Kou & Chen, 2017), metformin (Piskovatska et al., 2020), RSVA314 (Vingtdeux et al., 2011), and RSVA405 (Sarkar et al., 2005)), inhibiting inositol monophosphatase (lithium and (Sarkar et al., 2005)), other pathways (Zhang et al., 2017) (GTM-1, carbamazepine), and non-drug methods (Escobar et al., 2019) such as caloric restriction, physical exercise, etc. Besides aiming signal pathways for autophagy, an acidification disorder was observed in lysosomes of senescent cells. This disorder resulted in neurodegeneration with cognitive impairment (Colacurcio & Nixon, 2016). The use of acidic nanoparticles targeted toward lysosomes could restore lysosomal acidification in the context of presenilin-1 mutation (Lee et al., 2015). Interestingly, the genome-wide analysis revealed that the autophagy level changed in different AD periods (Lipinski et al., 2010). From this analysis, autophagy transcription may be upregulated in the early stage of AD, which may be attributed to the protective changes in the body. This is not contradictory to the treatment of enhanced autophagy. However, the specific mechanism of changes in autophagy at different disease stages still needs to be further clarified, and therapeutic schedules targeting autophagy in different stages are required.

### 3.3. Anti-inflammation strategies

As mentioned above, senescent cells can actively secrete SASP to change their microenvironment and lead to damage or aging of nearby cells. Many pro-inflammatory cytokines in SASP, such as the IL-1 superfamily, IL-6, IL-8, macrophage inflammatory proteins (MIPs), and so on, are the primary mediators of the harmful effects of senescent cells leading to chronic and low-level inflammation (Lopes-Paciencia et al., 2019; Birch & Gil, 2020). Multiple components of SASP can also induce senescence of adjacent cells in a paracrine manner, resulting in the in vivo transmission of senescence (Acosta et al., 2013). In addition to SASP, some reports have proposed chronic inflammation mediated by pathological changes representative of AD and the gut microbiota-brain axis as the central mechanism (Forloni & Balducci, 2018; Kinney et al., 2018; Sochocka et al., 2019). Therefore, anti-inflammatory therapeutics may be beneficial in delaying cellular senescence. The agents regulating SASP (often called senomorphics) may be regarded as an alternative to senolytics (Birch & Gil, 2020). Senomorphics can produce a marked effect in three ways: blocking SASP signaling cascades, preventing the secretion of SASP, and inhibiting the activity of single components of the SASP (Childs et al., 2017).

SASP signaling cascades include complex pathways, including the cyclic GMP-AMP synthase-stimulator of interference genes (cGAS-STING) pathway, the Janus kinase, and signal
transducer, activator of transcription pathway, GATA binding protein 4, p38MAPK, inflammasome, mTOR, and heat shock protein 90(HSP90). Notably, most SASP regulators seem to converge to NF-κB and the CCAAT/enhancer-binding protein β (C/EBPβ) (Sun et al., 2018; Lopes-Paciencia et al., 2019; Birch & Gil, 2020; Song et al., 2020). Several SASP signaling cascade pathways coincide with autophagy or apoptosis pathways, so related drugs such as rapamycin, metformin, curcumin, and inhibition of HSP90 may play an anti-aging role through different mechanisms (Moiseeva et al., 2013; Shehzad & Lee, 2013; Liu et al., 2016, 2017). Experiments targeting SASP signaling cascades have demonstrated that blocking signaling cascades can reduce the secretion of pro-inflammatory cytokines and effectively improve the function of aging tissues and organs. The role of cGAS in cellular senescence has received increased attention in recent years. For example, A151, a kind of cGAS inhibitor, reduces the production of pro-inflammatory cytokines, the inflammatory response of the injured brain, and protects neural function (Li et al., 2020).

As a set of proteins, the production of SASP undergoes a series of processes, including post-translational processing and secretion, before it takes effect, so proteases may be deemed as the key to regulating the activity of SASP (Childs et al., 2017). For instance, the IL-1 family matures after being cleaved by different proteases and achieves the maximum immune-stimulating activity. Proteases such as granzyme B, calpain, and others that can contribute to the maturation of pro-inflammatory cytokine may be good therapeutic targets (Childs et al., 2017). Besides achieving maximum immunity, blocking the process of SASP secretion from senescent cells is another method, and one therapeutic target is the ectodomain shedding mediated by metalloproteinase 17(ADAM17) (Effenberger et al., 2014; Afonina et al., 2015). At present, there are only a few studies on the maturation and secretion mechanism of SASP in senescent cells. More direct evidence of in vivo and in vitro models is required to prove that the above two promising methods can be applied for the clinical treatment of AD.

In addition, the third approach can be aimed at SASP components. Two studies showed that intracerebroventricular (ICV) anakinra—an IL-1R antagonist—and tocilizumab—an antibody against IL-6R-injection could significantly alleviate cognitive impairment and histopathological changes in AD models (Elicioğlu et al., 2016; Batista et al., 2021). Other SASP components such as TGF-β are also optional therapeutic targets. Thus, targeting SASP has a tremendous promising future.

The gut microbiota-brain axis successfully links neuroinflammation with peripheral mild chronic inflammation. The effort to restore intestinal flora balance has demonstrated anti-inflammation, anti-aging, and other positive effects on neurological function, such as improved cognitive function in the AD mouse model (Sochocka et al., 2019). Referring to anti-inflammatory drugs, NSAIDs are inevitably mentioned. The initial clue about the relationship between NSAIDs and AD came from rheumatoid arthritis patients who have long used NSAIDs, in which group the incidence of AD was unexpectedly low (McGeer et al., 1990). Subsequent comprehensive analysis of seventeen epidemiological studies confirmed that long-term NSAID intake is a preventive factor of AD in the normal elderly population (McGeer et al., 1996). Some studies have also confirmed the preventive effect of NSAIDs (Zandi et al., 2002; McGeer et al., 2016). Paradoxically, another large randomized study revealed that low-dose aspirin usage did not lead to any cognitive improvement after five years in participants over 50 years of age (Price et al., 2008). The contradictory results may indicate that NSAIDs can only play a preventive rather than therapeutic role and should be used at least a few years before the onset of the disease (Zandi et al., 2002). However, NSAIDs have not been recommended as a preventive drug for AD.

Due to the diversity of cells in the CNS and the complexity of the aging process and SASP, more fundamental studies are essential. Senescent cells are a double-edged sword, and the benefit is that senescent cells have an important role in inhibiting tumors, tissue repair, and so on (Figure 2) (Song et al., 2020). Therefore, successful anti-aging treatment must avoid undermining related benefits.

### 3.4. Stem cell therapy

While the mechanism has not been fully comprehended, stem cell therapy has been shown to promote neurogenesis and improve cognitive function in AD rodent models (Duncan & Valenzuela, 2017; Han et al., 2020). Stem cell trials designed to treat AD can be divided into four types: embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and neural stem cells (NSCs).

MSCs, which can be obtained from umbilical cord blood or the Wharton jelly, have been most studied due to the accessibility and relative ease of manipulation. MSCs injection has been proven to reach the brain, differentiate into neuron cells, and boost the growth and differentiation of local stem and progenitor cells in the hippocampus by activating the Wnt pathway in rodent models (Han et al., 2020). Although the low rate of neuronal differentiation limits direct neurogenesis of MSCs, many other mechanisms have also been proposed that can be neuroprotective, including reducing Aβ deposition and plaque formation, inhibiting Aβ- and tau-related neuron death, upregulating anti-inflammatory cytokines, and reversing inflammatory reaction (Duncan & Valenzuela, 2017; Han et al., 2020). At present, MSCs are the only stem cell experimented with in AD therapy in humans and in a clinical trial (Kim et al., 2015). The feasibility and safety of MSCs injection in human brains in AD patients have been confirmed, although no significant clinical effects on cognitive decline have been observed.

NSCs reside in the dentate gyrus of the hippocampus and subventricular zone of the lateral wall of the ventricle in adults and can derive all types of nerve cells. Human neural stem cells (hNSCs) can migrate and differentiate into neurons and glial cells when transplanted into the lateral ventricle of the brain of AD mouse models (Duncan & Valenzuela, 2017). Similar to MSCs, although the low differentiation rate of neurons also limits the neurogenic effect of NSC, its secretion of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and anti-inflammatory cytokines may have
great therapeutic potential to increase the density of neurons, synapses, and nerve fibers and reduce AD pathology to improve cognitive impairment in AD (Duncan & Valenzuela, 2017; Han et al., 2020). In aging mice transplanted with NSCs over-expressing choline acetyltransferase, improvement of cognitive function was observed, and the integrity recovery of cholinergic neurons in these mice was attributed to the increase in BDNF and NGF (Park et al., 2013).

ESCs is totipotent stem cell. HESCs transplantation can effectively mitigate the development of radiation-induced cognitive impairment in athymic nude rats (Acharya et al., 2009). However, direct transplantation of ESC into AD animal models leads to teratoma rather than neuron formation and is the primary limitation of the clinical translation. To circumvent this limitation, another tactic involves inducing ESC to differentiate into NSCs, MGE-like progenitor cells, or basic forebrain cholinergic neurons (BFCNs). In AD rodent model experiments, these cells can differentiate into cholinergic neurons and γ-aminobutyric acid neurons after transplantation to improve cognitive function (Duncan & Valenzuela, 2017; Han et al., 2020). Thus, iPSCs are currently widely used to build models of AD rather than treatments. In recent years, the development of advanced gene transduction and editing technologies has expanded the application potential of iPSCs (Brookhouser et al., 2017). By which, iPSCs can differentiate into normal neurons used for transplantation.

4. Application of nanoparticles

The BBB is the brain’s most important physiological barrier. On the one hand, BBB protects the CNS from toxic substances in the environment. On the other hand, it prevents drugs from entering the brain effectively (almost all macromolecule drugs and 98% small molecule drugs). BCECs are the primary structures that lead to BBB function. Unlike peripheral capillary endothelial cells, which have high permeability, BCECs have tight junctions that limit the paracellular transport of compounds from the blood to the brain. Tight junctions also cause extremely high transendothelial resistance (TEER), which inhibits the passive diffusion of chemicals (Gao, 2016; Ruan et al., 2021). Pericytes and astrocytes are the other two types of BBB cells. They contribute to the integrity of the BBB by embedding within and coating the basement membrane, as well as
inducing tight junction protein formation (Gao, 2016; Ruan et al., 2021). Only lipophilic drugs with a molecular weight of less than 500 Da can freely cross the BBB (Gao, 2016). As previously stated, the integrity of the BBB is compromised, and the permeability of the BBB is increased in the pathological changes of AD. However, vascular changes such as endothelial degeneration, disrupted transporter expression, perivascular accumulation of toxic products, and inflammation continue to obstruct drug delivery to the CNS (Sweeney et al., 2018). There are two approaches to delivering drugs into the CNS: bypassing the BBB or crossing it.

4.1. Strategies of overcoming the BBB

4.1.1. Bypassing the BBB

The two main methods for bypassing the BBB are directly delivering drugs into the CNS and intranasal administration (Wong et al., 2019; Binda et al., 2020). Direct drug delivery into the CNS includes invasive procedures such as ICV administration, intrathecal administration, and others. ICV administration entails drilling a hole in the skull and injecting drugs directly into the intracerebroventricular space. Due to the rapid renewal of CSF and the blood-CSF barrier, however, less than 1–2% of the administered drug can slowly diffuse into the brain parenchyma from ICV in a single injection (Furtado et al., 2018). Therefore, agents flowing into the subarachnoid space with CSF from ICV and being absorbed via leptomeningeal transport may be the main mechanism consistent with the absorption pathway of intrathecal administration (Papisov et al., 2013; Atkinson, 2017). Intrathecal administration, which involves injecting drugs into the subarachnoid space of the spinal cord via lumbar puncture, is the most practical and least invasive method used in the clinic. Agents administered via lumbar puncture diffuse from lumbar CSF to intracranial CSF via pulsatile mixing, enter the periarterial spaces with active CSF pumping, and then move into the brain parenchyma (Papisov et al., 2013). In CFS, the duration of agents at therapeutic concentration levels influences the therapeutic effect. Therefore, using a continuous micro-pump to keep drugs in the CSF may improve the therapeutic effect. However, invasive procedures may have limitations such as an injury during the procedure, infection, and poor patient acceptance.

Intranasal administration is a noninvasive method of circumventing the BBB. Intranasal administration is the shortest and most efficient route for drugs to enter the CNS (via extracellular diffusion, intraneuronal transport by the olfactory sensory neuron or the trigeminal nerve). Other advantages include rapid absorption, rapid onset, avoidance of first pass metabolism, and high patient acceptance (Gao, 2016; Furtado et al., 2018). However, the high solubility of drugs (due to the limitation of a single dose), nasal epithelial barriers (only 5% of the total nasal surface area in humans belongs to the olfactory surface area), skilled operations (agents must be sprayed deep into the nasal cavity), and other factors pose challenges (Furtado et al., 2018). Many absorption enhancers or modulators, as well as nanoparticles, have been developed to address these challenges (Gao, 2016).

4.1.2. Crossing through the BBB

The most common route for drugs to enter the brain is via the BBB, which includes CMT, RMT, AMT, cell-mediated transport, paracellular transport, and passive transcellular diffusion (Figures 3 and 4). The majority of the nutrients required by the brain are transported from the blood to the CNS via a specific carrier or transporter. Glucose transporter-1 (GLUT1) and amino acid transporters are commonly high expressed on the BBB (Gao, 2016). CMT thus refers to assisting drug delivery through these specific influx transporters. RMT and AMT transport agents in a process known as transcytosis. Many receptors are highly expressed on the BBB, including transferrin (Tf) receptor, insulin receptor (IR), low-density lipoprotein receptor-related protein (LRP), diphtheria toxin receptor (DTR), and others (Gao, 2016; Ruan et al., 2021). The binding of corresponding ligands to these receptors causes RMT. RMT is currently the most successful and widely studied delivery method. Interestingly, in the context of AD, influx transport-related BBB changes include, but are not limited to, RAGE up-regulation and DTR up-expression, decreased IR sensitivity, and LRP and GLUT1 reduction (Sweeney et al., 2018). Tf receptor expression did not change significantly on the BBB in AD, and Tf receptor was also the most commonly targeted receptor for RMT (Gao, 2016; Sweeney et al., 2018). Other functional ligands have also been developed to successfully promote drug delivery. AMT is another electrostatic interaction-mediated transcytosis (creating a cationic surface charge on the cargo or conjugating the cargo with a positively charged moiety, such as a cell penetrating peptide) (Gao, 2016; Furtado et al., 2018). However, when compared to RMT, AMT has a lower affinity, and poor targeting of BBB and positively charged compounds may cause BBB damage (Furtado et al., 2018; Ruan et al., 2021). Cell-mediated transport is a distinct mode of transfer. Cell-mediated transport is distinct in that agents are designed to be absorbed by peripheral immune cells before entering the CNS via immune cell chemotaxis in the case of neuroinflammation (Batrakova et al., 2011). Cell-mediated transport has the potential to deliver drugs to the inflammatory microenvironment of senescent cells, but the compatibility of drugs and carriers is the primary issue to be addressed. Finally, tight junctions prevent nearly all drugs from entering the brain via paracellular transport. Currently, the BBB can be temporarily opened using chemical and physical methods such as borneol, activation of A1 or A2A adenosine receptors, and focused ultrasound (FUS), resulting in a significant improvement in drug delivery efficiency (Gao, 2016). However, short-term cognitive impairment and other adverse events following FUS in AD should be monitored.

4.2. Advantages of nanoparticles

Nanoparticles refer to nanomaterials that carry biomedical functional molecules by physical adsorption, encapsulation, molecular self-assembly, or chemical bonding. Nanoparticles are typically divided into several categories, including lipid-based NPs, polymeric NPs, inorganic NPs, nanogels, etc. Nanoparticles can be engineered to have varying sizes, shapes,
hollow or solid structures, and tunable chemical, biological, magnetic, electronic, and optical properties to improve drug loading, stability, bioavailability, and targeting (Kim et al., 2010). Thus, nanoparticles can increase the efficiency with which agents enter the CNS and decrease consumption in peripheral circulation by targeting transportation. Nanoparticles, particularly those with specific functionalization, can play an important role in the first four pathways of BBB crossing.

### 4.3. Nanoparticles-based anti-aging agents

In this section, we mainly refer to some drugs that are currently considered to have anti-aging effects applied for AD. With the aid of nanoparticles, these anti-aging agents can improve the condition of AD more significantly via anti-inflammatory or alleviating pathological changes. Nanoparticles-based anti-aging treatments in AD are expected to exert promising anti-AD therapeutic efficacy in future studies.
4.3.1. Lipid-based NPs

Lipid-based NPs are usually stable and nontoxic spherical vesicles composed of one or more phospholipid layers and are well suited to brain drug delivery applications. Liposomes and solid lipid NPs (SLNs) are the most common types. The core of SLNs is biocompatible lipids, which can solubilize lipophilic molecules, while liposomes have a hydrophilic core (Furtado et al., 2018). Lipid-based NPs have the features of low toxicity and immunogenicity. However, the stability of lipid-based NPs in the gastrointestinal tract and drug loading capacity should be further improved.

‘Naked’ liposomes can hardly carry drugs directly crossing through the BBB into the brain via passive transport. However, functionalized or modified liposomes to change the physical and chemical properties of the surface can bring the penetration capacity into full play by targeting transport; besides, these can also be designed to aim at specific targets related to AD (Ross et al., 2018). Curcumin-associated liposome delivery systems, for example, have a high affinity for Aβ plaques and, after being modified by PEGylated lipid coating, can attach anti-transferrin monoclonal antibodies for BBB transport mediation (Mourtas et al., 2014). In another study (Meng et al., 2015), a novel nanostructured lipid carrier (NLC), which was modified with lactoferrin (Lf) and loaded with curcumin (Cur-loaded Lf-mNLC), was designed for brain-targeted delivery. Lf-mNLC showed the maximum absorption of the brain capillary endothelial cells (which was 1.39 times higher than NLC) in vitro conditions, and Cur-loaded Lf-mNLC showed significant improvement in the pathological injury of neurons in rats. Another Lf functionalized liposome...
RMP-7-Lf-QU-LS, which is quercetin (QU) encapsulated liposome graft with RMP-7 and Lf, could be recognized by capillary endothelial cells via Lf receptor (LfR) and enhanced the penetration capacity of QU with low cytotoxicity to BBB, as well as prevented Aβ caused neurodegeneration and improved the viability of neurons in vitro model (Kuo & Tsao, 2017). Researchers also designed quercetin- and rosmarinic acid-loaded liposomes with conjugated phosphatidic acid and apolipoprotein E (ApoE-QU-RA-PA-liposomes), which can effectively penetrate the BBB without damaging the BBB after ApoE modified and promote neurons recovery from Aβ induced neurotoxicity by degrading Aβ and anti-inflammation, both in vivo and in vitro (Kuo et al., 2020). The permeability of BBB of resveratrol-loaded SLNs functionalized by ApoE also increased significantly (1.8-fold higher) than non-functionalized SLNs. The entrapment efficiency of SLNs for resveratrol reached 90% and resveratrol was released in a controlled and linear manner at the target site (Neves et al., 2016). Other modes (insulin and insulin-like growth factors, low-density lipoprotein, cell-penetrating peptides, etc.) of functionalized lipid-based NPs had also been recommended (Ross et al., 2018).

In addition to encapsulating anti-aging agents into the carriers, conjugating curcumin on the surface of liposomes by covalent bonding showed high affinity toward amyloid deposits in APP/PS1 transgenic mouse models and postmortem brain tissue of AD patients. Further, it also strongly inhibited Aβ fibril formation (Lazar et al., 2013; Kuo et al., 2018). The analogous designs which can deliver an agent from BBB to a region of interest or target cells in the CNS—secondary targeting drug delivery—have also been extended to other types of nanoparticles.

### 4.3.2. Polymeric NPs

Polymeric NPs are a series of promising delivery carriers with characteristics of high drug loading, controllable drug release, and ease of modification. There is a great variety of polymeric NPs, including nanocapsules, nanospheres, micelles, dendrimer, polymersomes, and polyplexes, and Polymeric NPs are composed of biodegradable or biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA), poly(alkyl cyanoacrylate), PEG, poly(amoidoamine) (PAMAM) and so on. PLGA is the most commonly used to synthesize nanocapsules, while PAMAM is dendrimers. In one study (Tiwari et al., 2014), after 24h of in vitro treatment with simple curcumin-loaded PLGA NP (cur-PLGA-NPs), most of cur-PLGA-NPs were internalized into neural stem cells and neurons. In vivo, cur-PLGA-NPs could cross the BBB of rats and then localized in the hippocampus after intraperitoneal administration. In the process, curcumin was sustained and slowly released from NPs. Besides, compared with the same doses of free curcumin, the curcumin level in the brain of the cur-PLGA-NPs treatment group increased by 2.1 to 2.8 times, and hippocampus and neuronal cell proliferation was enhanced too. Cur-PLGA-NPs also showed efficacy even at the dose of 0.5 mg after directional injection in the hippocampus, while a high dose of curcumin did not show significant enhancement of neurogenesis. Some existing and potential drugs beneficial to AD (galantamine, memantine, resveratrol, quercetin, dexibuprofen, etc.) encapsulated by polymeric NPs also showed a significantly elevated therapeutic index (Wong et al., 2019; Binda et al., 2020).

Similar to lipid-based NPs, polymeric NPs can also be functionalized to enhance penetration and targeting. Recent research showed conjugation of PLGA NPs with CRT peptide (a cyclic iron-mimic peptide that targets Tfr) increased their permeation across the BBB (Huang et al., 2017). Curcumin-PLGA NPs conjugated with Tet-1 (a 12-amino acid peptide with the binding characteristics of tetanus toxin) can raise the uptake of the neuron (Mathew et al., 2012). G7(Gly-L-Phe-DThr-Gly-L-Phe-L-Leu-LSer(O-b-D-Glucose)-CONH2), B6 peptide (targeting Tfr as a substitute for transferrin protein), and 83-14 monoclonal antibody (MAb) modified curcumin-PLGA NPs also showed high-performance in permeation of the BBB and potential application in the treatment of AD (Barbara et al., 2017; Fan et al., 2018; Kuo & Tsai, 2018). Researchers recently developed R@(ox-PLGA)-KcD, a novel nanocleaner. R@(ox-PLGA)-KcD significantly reduced the inflammatory microenvironment, Aβ and p-Tau burden in the brain, and rescued memory deficits in an AD mouse model. Special components and structure were credited with excellent treatment outcomes (Lei et al., 2021). R@(ox-PLGA)-KcD is made up of PLGA linked to ROS-responsive Polyl-ox (made from inositol and oxalyl chloride) and then loaded with rapamycin (promoting autophagy). KLVFFC and C-Acp-Cyclo (CDAGRKQKC) were linked with DSPE-PEG2000-Mal and DSPE-hyd-PEG5000-Mal, respectively, to form DSPE-PEG2000-KLVFF and DSPE-hyd-PEG5000-DAG. They were then modified on the core’s surface to form an integrated nanocleaner. R@(ox-PLGA)-KcD can specifically target BBB at lesions by targeting its receptor connective tissue growth factor C-Acp-Cyclo (CTGF). R@(ox-PLGA)-KcD cleaved DAG via lysosome in endothelial cells, and the remainder of the nanocleaner [R@(ox-PLGA)-K] was exocyted into the brain parenchyma (Lei et al., 2021). Other polymers, in addition to PLGA, have recently received a lot of attention. ApoE-mediated poly(butyl) cyanoacrylate nanoparticles with curcumin (ApoE3-C-PBCA) are an effective drug delivery system. The increased uptake of curcumin and the synergism between ApoE3 and curcumin were attributed to ApoE3-C-enhanced PBCA’s neuroprotection and anti-amyloidosis (Mulik et al., 2010). Furthermore, Ab peptide (KLVFAEAD) modified micelles containing curcumin (APLB/ CU) can cross the BBB and be actively internalized by neurons or activated microglia via RAGE. APLB/CU improved cognitive function by alleviating the microenvironment of APP/PS1 mice brain, such as protein plaque and neuroinflammation, via a transportation-mimicked pathway (Lu et al., 2019). Recently, a study linked polycaprolactone (PCL) terminus-modified PEG with RAP peptide (a specific ligand of RAGE) via ROS-sensitive sulfur ether linker (MAH-EDT) and then self-assembled with tacrolimus (FK506) and ibuprofen to form Ibu&FK@RNPs (He et al., 2022). After 21 days of Ibu&FK@RNPs administration, the synaptic density and water maze test results of AD mice were similar to the wild control group. Aβ burden and the activation of astrocytes in the Ibu&FK@RNPs group were 1.64 and 12.78 times lower than the untreated group, respectively. Changes in the Ibu&FK@RNPs group were all much better than those
in ibu&FK@NPs (non-RAP peptide modified) group (He et al., 2022). Thus, targeting RAGE has the potential to penetrate BBB efficiently.

Compared with the other nanoparticles, dendrimers have rich terminal functional groups that can provide multiple attachment sites for the conjugation of drugs and other targeted components, and chemical bonds can be hydrolyzed in cells, which is conducive to drug release (Al-Azzawi et al., 2018). Dendrimers are hyperbranched polymer macromolecules with a dendritic structure. Non-modified PAMAM dendrimer had been proved to pass through impaired BBB induced by inflammation and then located in the Intracranial inflammatory microenvironment in rabbit models. Loading anti-inflammation drugs (N-acetyl-L-cysteine or tesaglitazar) can significantly enhance bioavailability and effectively inhibit inflammatory response (Kannan et al., 2012; DeRidder et al., 2021). In a recent study, a multi-target dendrimer, namely PBPI, was composed of 8-arm hydroxylating PEG linked with ROS-sensitive alkynyl and then in conjunction with p-Nrf2. With the modification of the Ab peptide, they can effectively target the inflammatory microenvironment of AD to reduce inflammation and ROS, decrease the Ab burden, and eventually improve cognitive functions in AD model mice (Liu et al., 2021). To overcome the main disadvantage of flurbiprofen—low brain permeability-applied for neuroinflammation, poly(Epsilon-Lysine) dendrimer was designed to increase the permeability of flurbiprofen to the BBB in vitro (Al-Azzawi et al., 2018). Dendrigraft poly-L-lysine (DGL) is used for gene delivery due to its high gene transfection efficiency (Cai et al., 2020). T7 peptide (HAIYPRH, targeting Tf receptor) was modified onto DGL with acid-cleavable long-chain PEG (D-DT) after Dp (an all D-amino acid inhibitor inhibiting tau phosphorylation) and Tet1 (a 12-amino-acid peptide targeting neuron) were modified onto DGL with short-chain PEG (D-DT) (D-DTCT7). Finally, static electricity was used to load the BACE1 siRNA onto the D-DTCT7 to synthetize D-DTCT7/siRNA (Cai et al., 2020). D-DTCT7/siRNA was shown to target the BBB and neurons, inhibit the formation of Ab and p-Tau-related fiber tangles in neurons, and significantly improve cognitive impairment in AD mice. The superiority of dendrimers is apparent. However, with the more branches and larger molecular weight of dendrimers, although the drug loading increased, it was accompanied by the increased toxicity of carriers and a decrease in clearance rate and drug release rate (Al-Azzawi et al., 2018). Balancing the pros and cons requires further research.

4.3.3. Inorganic NPs

Inorganic NPs include gold NPs (AuNPs), magnetic NPs (MNPs), silver NPs, titania NPs, ceramic NPs, and many others. Different kinds and sizes of inorganic NPs have different physicochemical properties. Compared with the first two types of NPs, inorganic NPs have been relatively rarely examined to treat AD. Based on the unique physicochemical properties (ultra-small size, inert chemical property, excellent biocompatibility, ease of functionalization), AuNPs can be a potential drug delivery carrier (Gao et al., 2017). In vitro, an experiment using Ab(1–40) as an example revealed that large AuNPs (average diameter: 36.0 ± 3.0 nm, 18.1 ± 3.0 nm) coated by L-glutathione (GSH) accelerated the growth of Ab fibrils, whereas smaller AuNPs (average diameter of 6.0 ± 2.0 nm) largely suppressed this process, while gold nanoclusters (AuNCs; average diameter of 1.9 ± 0.7 nm) showed much stronger inhibition effect toward Ab fibrillation. Interestingly, complete inhibition can be observed when AuNCs concentration reaches 10 ppm (1 ppm = 1 µg·mL⁻¹) or higher, and a similar inhibition effect of AuNCs was also observed for Ab(1–42) (Gao et al., 2017). However, the study pointed out that AuNPs with a size of under 40 nm could cross the BBB most efficiently, while a size smaller than 4–5 nm possibly induces cytotoxicity by penetrating the nucleus and binding DNA due to very high surface area over volume ratios. Therefore, the size of AuNPs between 10 nm to 30 nm seems to be the ideal choice (Soenen et al., 2011).

AuNPs with smaller diameters have a stronger inhibition of Ab fibrillation, but how to avoid cytotoxicity caused by too small size AuNPs, the surface modification should be considered. A study indicated that chiral L- and D-GSH coated AuNPs with diameters of 3.3 nm, namely L3.3 and D3.3, can be transported from the blood circulation to the brain by intravenous injection and reduced Ab deposition without obvious cytotoxicity at the experimental dose (25 mg/kg), and D3.3 showed higher brain distribution and significant improvement in spatial learning and memory (Hou et al., 2020). In another study, the researchers grafted polyoxometalates with Wells–Dawson structure (POMD) which showed the inhibition effect on Ab aggregation onto the surface of AuNPs (average diameter of 21.7 nm) and then conjugated with the N-acetyl-Cys-LPFFD peptide (N-Ac-CLPFFD)–an effective β-sheet breaker peptide–to form AuNPs@POMD-pep, it showed efficient blood-brain barrier penetration and synergistic effects in clearing Ab and inhibiting Ab-induced cytotoxicity and oxidase activity (Gao et al., 2015). Curcumin functionalized AuNPs (Au-curcumin) better enhanced the inhibition of Ab fibrillation and disintegration of amyloid fibrils in a dose-dependent manner, compared with similar concentrations of curcumin or AuNPs alone (Palmal et al., 2014).

Besides AuNPs, inorganic NPs, including carbon NPs, Fe3O4 magnetic nanoparticles (MNPs), cerium oxide nanoparticles (CeO2-NPs), and selenium NPs have also been shown to cross the BBB, inhibit the aggregation of Ab, disaggregate Ab fibrils, alleviate Ab-mediated peroxidase activity and cytotoxicity, and protect neurons and synapses (Bilal et al., 2020). Inorganic NPs are developing rapidly and have a great variety. Thus, inorganic NPs can act as multifunctional DDSs combined with anti-aging agents for AD.

4.3.4. Nanogels

Nanogels are a class of nano level three-dimensional polymers with temperature and optical controllability composed of polymers through chemical and/or physical crosslinking and can improve drug release (Li et al., 2012). Compared with other nanoparticles, nanogels have high drug loading, sustained release, distinctive biocompatibility, and colloidal stability. They can also be surface-functionalyzed and effectively pass across the BBB (Shah et al., 2020). Insulin
conjugated to the carboxyl-functionalized poly(N-vinyl pyrrolidone) nanogel system (NG-In) can cross the BBB mediated by InR in vitro model (Picone et al., 2016). NG-In protected insulin from protease degradation and allowed its safe delivery to the target site with the aim of anti-inflammation and anti-Aβ in the CNS (Picone et al., 2016). It also provided a new drug delivery system for AD. Although studies about nanogels focused on AD are relatively few now. However, many nanogels such as cholesterol ε-polysine (CEPL) nanogel, poly (vinyl alcohol) nanogel, PEG-b-PMAA nanogel, polyethylene glycol conjugated nanogel have been used to load drugs for the treatment of intracranial infection, tumor, ischemia, and other diseases and significantly improved therapeutic effects (Shah et al., 2020). Nanogels are expected to be widely studied in the anti-aging treatment of neurodegenerative diseases.

4.4. Challenges and restrictions

Available evidence indicated that nanoparticles-based anti-aging agents have more robust stability and superior bioavailability in vivo. Nanoparticles have broad prospects as DDSs for AD. Unfortunately, anti-aging treatment for AD based on nanoparticles is still in the laboratory stage. Currently, the challenges and restrictions of nanoparticles are derived from their biocompatibility and stability.

When nanoparticles are used in CNS diseases, the primary concern is toxicity, particularly neurotoxicity. Neurotoxicity can be avoided by reducing the retention of nanoparticles and metabolites in the brain. Therefore, the inevitable question is how nanoparticles are removed from the CNS. Extracellular degradation by metabolizing enzymes, internalization and subsequent degradation by neurons and glial cells, entrance into CSF bulk flow and reabsorption into the bloodstream or cervical lymphatics, and brain-to-blood efflux via abluminal transporters (ATP-binding cassette transporter, P-glycoprotein) (Gao et al., 2017). Other constraints, such as the tendency of nanoparticles to aggregate abnormally in storage, lysosomal trafficking, protein corona formation, and rapid clearance from circulation, can be partially overcome by specific modified surface properties. Stabilizing coatings and cryoprotectants can be used to prevent abnormal aggregation. Coating with PEG, poloxamine 908, polysorbate 80, and other modified agents can reduce protein corona formation and increase metabolic time. Cationic nanoparticles, nanoparticles conjugated with acid-responsive compounds, and special ligands (FCS sAb and ligand targeting DTR) are lysosomal-escapable (Kannan et al., 2012; Barbara et al., 2017; Gao et al., 2017; Furtado et al., 2018).

Besides this, it is only in the first stage that the nanoparticles penetrate the BBB for AD treatment. More attention should be paid to formulating secondary or multi-targeting drug delivery systems for CNS diseases (Kannan et al., 2012; Barbara et al., 2017). Summarily, the toxicity and biocompatibility of NPs, the mode of drug release based on nanoparticles, transport of NPs oriented toward the lesion site, and metabolism or clearance of nanoparticles from CNS still need long-term and extensive studies.

5. Conclusion and future perspective

The etiology of AD has not been delineated completely. At present, the clinical treatment of AD can only improve relevant symptoms, and the studies have always been attempting to find treatment methods to cease or reverse the course of the disease. However, research on treatments such as Aβ monoclonal antibodies targeting pathological changes is not plain sailing. The primary problems are that the experimental results do not meet expectations, the indications are limited to the early or middle stage of the disease, and there are obvious side effects such as cerebral microbleeds and others.

Cellular senescence is an alternative choice to find the etiology of AD from another perspective and seek targeting therapeutics. While being promising, there are also many challenges. At first, most of the current studies on the senescent cells in the CNS focus on glial cells. Due to the peculiarity and complexity of the CNS, future studies are expected to verify the aging evidence of various neural cells and elaborate on the interaction between various senescent cells and the causal relationship between them and AD. Second, there are only a few studies on the anti-aging treatment of AD, especially when based on nanoparticles. Currently, studies on anti-aging therapeutics such as senolytics, enhancing autophagy, anti-inflammation, and stem cell therapy applied to AD models have proved its great potential as DMT, including alleviation of both pathology and symptom in AD. Although they are still in the phase of exploration and preliminary development, they may be promising clinical treatments in the near future. More studies are expected to combine anti-aging therapeutics with nanoparticles to treat neurodegenerative diseases such as AD in the future. Besides this, anti-aging therapy has been proved to improve the function of other tissues and organs, such as bone and joint degenerative diseases, cardiovascular diseases, muscle atrophy, and others. These diseases are common in the elderly. Given the age of onset of AD, perhaps CNS anti-aging therapeutics should not be treated in isolation but rather as part of systemic anti-aging therapeutics.

Finally, regarding the new DDSs, the nanoparticles are conducive to agent delivery, including the penetration of anti-aging agents through the BBB and targeted delivery, and can significantly improve pharmacokinetics and bioavailability. This review only discusses several main types of nanoparticles. Nanoparticles represent an emerging field with great potential, and numerous new types of nanoparticles are being explored. The specific surface modification of nanoparticles can make them efficiently cross the BBB and be located at different targets after entering the CNS. In another way, controllable drug release mode and the synergy between drugs, drugs, and nano carriers can enhance the bioavailability (Su et al., 2015; Huang et al., 2016). Furthermore, altering the drug administration modalities, such as oral administration, subcutaneous injection, and transdermal patching may accompany better medication compliance and safety. Nonetheless, its transition to clinical practice is still a long-term and complex task. Furthermore, because many types of tumor cells and immune cells have the proclivity and ability to migrate into the CNS, DDSs based on exosomes...
and apoptotic bodies derived from cytomembranes (tumor cells, immune cells, and others) have demonstrated significant advantages and potential in crossing the BBB. As a result, they have received increased attention in recent years, and they offer promising prospects for improving and perfecting AD therapeutics (Wang et al., 2021).

### Executive Summary:

**Anti-aging treatment AND AD**

- AD is heavy health and economic burden for the whole world.
- There are still no significantly effective DMTs for AD until now.
- Cellular senescence of the CNS is correlated with AD closely.
- Anti-aging can be a promising treatment for delaying and reversing the course of Alzheimer’s disease.

**Application of nanoparticles**

- The BBB hinders the entry of many agents into the CNS.
- Nanoparticles can promote the stability and efficiency of anti-senescent drugs and lower their loss while penetrating BBB.
- Nanoparticles can also improve drug targeting.

Lipid-based NPs, Polymeric NPs, Inorganic NPs, and Nanogels have been used widely for drug delivery of AD and are hopeful to enhance anti-aging treatment.

### Disclosure statement

No potential conflict of interest was reported by the authors.

### Funding

This research was funded by Science and Technology Support Projects in Biomedicine Field of Shanghai Science and Technology Commission, grant number #19441907500, Shanghai Natural Science Foundation, grant number 22ZR147750, Innovative clinical research project of Changzheng Hospital, grant number 2020 YLCYJ-Y 02, Characteristic medical service project for the Army of Changzheng Hospital, grant number 2020 CZWJFW 12, National Natural Science Foundation of China, grant number 82072051 and National Natural Science Foundation of China, grant number 81771964.

### ORCID

Jie Gao [http://orcid.org/0000-0003-1317-2445](http://orcid.org/0000-0003-1317-2445)
You Yin [http://orcid.org/0000-0001-9657-9720](http://orcid.org/0000-0001-9657-9720)

### References

Acharya MM, Christie L-A, Lan ML, et al. (2009). Rescue of radiation-induced cognitive impairment through cranial transplantation of human embryonic stem cells. Proc Natl Acad Sci U S A 106:19150–5.

Acosta JC, Banito A, Wuestefeld T, et al. (2013). A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 15:978–90.

Aducanumab. (2021). LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD). Available at: [http://www.ncbi.nlm.nih.gov/books/NBK571858/](http://www.ncbi.nlm.nih.gov/books/NBK571858/)

Afonina IS, Muller C, Martin SJ, Beyaert R. (2015). Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity 42:991–1004.

Al-Azzawi S, Marsheta D, Guildford AL, et al. (2018). DendrimERIC poly(eopilson-lysine) delivery systems for the enhanced permeability of flurbiprofen across the blood-brain barrier in Alzheimer’s disease. UMS 19:3224.

Alexander GC, Emerson S, Kesselheim AS. (2021). Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA 325:1717–8.

Al-Mashhadi S, Simpson JE, Heath PR, Medical Research Council Cognitive Function and Ageing Study, et al. (2015). Oxidative glial cell damage associated with white matter lesions in the aging human brain. Brain Pathol 25:565–74.

Alzheimer’s Association. (2021). Alzheimer’s disease facts and figures. Alzheimer’s Dement 17:327–406.

Amor C, Feucht J, Leibold J, et al. (2020). Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583:127–32.

Atkinson AJ. (2017). Intracerebroventricular drug administration. Transl Clin Pharmacol 25:117–24.

Baker DJ, Wijshake T, Tchkonia T, et al. (2011). Clearance of p16nk4a-positive senescent cells delays ageing-associated disorders. Nature 479:232–6.

Barbara R, Belletti D, Pederzoli F, et al. (2017). Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates. Int J Pharm 526:413–24.

Batista AF, Rody T, Forny-Germano L, et al. (2021). Interleukin-1β mediates alterations in mitochondrial fusion/fission proteins and memory impairment induced by amyloid-β oligomers. J Neuroinflammation 18:54.

BatraKova EV, Gendelman HE, Kabanov AV. (2011). Cell-mediated drug delivery. Expert Opin Drug Deliv 8:415–33.

Bhanu MU, Mandraju RK, Bhaskar C, Kondapi AK. (2010). Cultured cerebellar granule neurons as an in vitro ageing model: topoisomerase IIB as an additional biomarker in DNA repair and aging. Toxicol In Vitro 24:1935–45.

Bhat R, Crowe EP, Bitto A, et al. (2012). Astrocyte senescence as a component of Alzheimer’s disease. PLoS One 7:e45069.

Bilal M, Barani M, Sabir F, et al. (2020). Nanomaterials for the treatment and diagnosis of Alzheimer’s disease: an overview. Nanomolcpute 20:100251.

Binda A, Murano C, Rivolta I. (2020). Innovative therapies and nanomedicine applications for the treatment of Alzheimer’s disease: a State-of-the-Art (2017–2020). Int J Nanomed 15:6113–35.

Birch J, Gil J. (2020). Senescence and the SASP: many therapeutic avenues. Genes Dev 34:1565–76.

Bitto A, Sell C, Crowe E, et al. (2010). Stress-induced senescence in human and rodent astrocytes. Exp Cell Res 316:2961–8.

Bloom GS. (2014). Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71:505–8.

Boisvert MM, Erikson GA, Shokhirev MN, Allen NJ. (2019). Astrocyte senescence as a component of Alzheimer’s disease pathogenesis. JAMA Neurol 76:1935–45.

Bourdoulaki SG, Bouroudaki MA, Kostopoulos TG, et al. (2019). Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583:127–32.

Bourgeois B, Madl T. (2018). Regulation of cellular senescence via the FOXO4-p53 axis. FEBS Lett 592:2083–97.

Brookhouser N, Raman S, Potts C, Brafman DA. (2018). Foxo-dependent regulation of senescence. Cell 172:1244–56.

Brown WR, Thore CR. (2011). Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol 37:56–74.

Brown WR, Thore CR. (2011). Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol 37:56–74.

Bussian TJ, Aziz A, Meyer CF, et al. (2018). Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562:578–82.
Caccamo A, De Pinto V, Messina A, et al. (2014). Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J Neurosci 34:7988–98.

Cai L, Yang C, Jia W, et al. (2020). Endo/lysosome-escapeable delivery depot for improving BBB transcytosis and neuron targeted therapy of Alzheimer’s disease. Adv Funct Mater 30:1909999.

Cai Y, Zhou H, Zhu Y, et al. (2020). Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res 30:574–89.

Cai Z, Xiaoy M. (2016). Oligodendrocytes and Alzheimer’s disease. Int J Neurosci 126:97–104.

Campisi J. (2011). Cellular senescence: putting the paradoxes in perspective. Curr Opin Genet Dev 21:107–12.

Chae J-B, Jang H, Son C, et al. (2021). Targeting senescent retinal pigment epithelial cells facilitates retinal regeneration in mouse models of age-related macular degeneration. GeroScience 43:2809–33.

Childs BG, Durik M, Baker DJ, van Deursen JM. (2015). Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med 21:1424–35.

Childs BG, Gluscevic M, Baker DJ, et al. (2017). Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov 16:718–35.

Colacurcio DJ, Nixon RA. (2020). Identification of p21-dependent senescence-like phenotype driven by a DNA damage p21-dependent senescence-like phenotype driven by a DNA damage

Daneman R, Prat A. (2015). The blood-brain barrier. Cold Spring Harb Perspect Biol 7:a020412.

DeRidder L, Sharma A, Liaw K, et al. (2021). Dendrimer-tesaglitazar conjugate induces a phenotype shift of microglia and enhances β-amyloid phagocytosis. Nanoscale 13:939–52.

Dong W, Cheng S, Huang F, et al. (2011). Mitochondrial dysfunction in long-term neuronal cultures mimics changes with aging. Med Sci Monit 17:8981–96.

Duncan T, Valenzuela M. (2017). Alzheimer’s disease, dementia, and stem cell therapy. Stem Cell Res Ther 8:111.

Effenberger T, von der Heyde J, Bartsch K, et al. (2014). Senescence-associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding. Faseb J 28:4847–56.

Elcióglu HK, Aslan E, Ahmad S, et al. (2016). Tcilizumab’s effect on neuroinflammation in Alzheimer’s disease. Nat Commun 8:422.

Fanoudi S, Hosseini M, Alavi MS, et al. (2018). Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer’s disease. Drug Deliv 25:1091–102.

Fanouri S, Hosseini M, Alavi MS, et al. (2018). Everolimus, a mammalian target of rapamycin inhibitor, ameliorated streptozotocin-induced learning and memory deficits via neurochemical alterations in male rats. Excli J 17:999–1017.

Forloni G, Balducci C. (2018). Alzheimer’s disease, oligomers, and inflammation. J Alzheimers Dis 62:1261–76.

Franceschi C, Campisi J. (2014). Chronic inflammation (inflamaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 69:S54–S9.

Fuhrmann-Stroissnigg H, Ling YY, Zhao J, et al. (2017). Identification of HSP90 inhibitors as a novel class of senolytics. Nat Commun 8:422.

Furtado D, Björnmal M, Ayton S, et al. (2018). Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases. Adv Mater 30:e1801362.

Gao G, Zhang M, Gong D, et al. (2017). The size-effect of gold nanoparticles and nanoclusters in the inhibition of amyloid-β fibrillation. Nanoscale 9:4107–13.

Gao H. (2016). Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 6:268–86.

Gao N, Sun H, Dong K, et al. (2015). Gold-nanoparticle-based multifunctional-α-muromelic β-inhibitor against Alzheimer’s disease. Chemistry 21:829–35.

Gao X, Gu X, Chen H. (2017). Chapter 3 - The distribution and elimination of nanomaterials in brain. In: Jiang X, Gao H, eds. Neurotoxicity of nanomaterials and nanomedicine. Academic Press, London/San Diego (CA)/Cambridge (MA)/Oxford, 59–74. Available at: https://www.sciencedirect.com/science/article/pii/B9780128045985000039.

Geng Y-Q, Guan J-T, Xu X-H, Fu Y-C. (2010). Senescence-associated beta-galactosidase activity expression in aging hippocampal neurons. Biochem Biophys Res Commun 386:866–9.

Giacci MK, Bartlett CA, Smith NM, et al. (2018). Oligodendroglia are particularly vulnerable to oxidative damage after neurotrauma in vivo. J Neurosci 38:6491–504.

Glick D, Barth S, Macleod KF. (2010). Autophagy: cellular and molecular mechanisms. J Pathol 221:3–12.

Grimm A, Eckert A. (2017). Brain aging and neurodegeneration: from a mitochondrial point of view. J Neurochem 143:418–31.

Guerrero A, Herranz N, Sun B, et al. (2019). Cardiac glycosides are broad-spectrum senolytics. Nat Metab 1:1074–88.

Hamano T, Gendron TF, Causevic E, et al. (2008). Autophagic-lysosomal perturbation enhances tau aggregation in transfectedants with induced wild-type tau expression. Eur J Neurosci 27:1119–30.

Han F, Bi J, Qiao L, Arancio O. (2020). Stem cell therapy for Alzheimer’s disease. Adv Exp Med Biol 1266:39–55.

Hansen M, Rubinsztein DC, Walker DW. (2018). Autophagy as a promoter of longevity: insights from model organisms. Nat Rev Mol Cell Biol 19:579–93.

Hara T, Nakamura K, Matsui M, et al. (2006). Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441:885–9.

He N, Jin W-L, Lok K-H, et al. (2013). Amyloid-β(1–42) oligomer accelerates senescence in adult hippocampal neural stem/progenitor cells via formylpeptide receptor 2. Cell Death Dis 4:e4924.

He X, Wang X, Yang L, et al. (2022). Intelligent lesion blood–brain barrier targeting nano-missiles for Alzheimer’s disease treatment by anti-neuroinflammation and neuroprotection. Acta Pharm Sin B 12:1987–99.

Hebert LE, Bienias JL, Aggarwal NT, et al. (2010). Change in risk of Alzheimer disease over time. Neurology 75:786–91.

Heneka MT, Carson MJ, El Khoury J, et al. (2015). Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14:388–405.

Hou K, Zhao J, Wang H, et al. (2020). Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer’s disease. Nat Commun 11:4790.

Huang J, Tao C, Yu Y, et al. (2016). Simultaneous targeting of differentiated breast cancer cells and breast cancer stem cells by combination of doxetaxel- and sulforaphane-loaded self-assembled poly(D,L-lactide-co-glycolide)/hyaluronic acid block copolymer-based nanoparticles. J Biomed Nanotechnol 12:1463–77.

Huang N, Liu S, Liu X-G, et al. (2017). PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s disease mice. Oncotarget 8:81001–13.

Ishikawa S, Ishikawa F. (2020). Proteostasis failure and cellular senescence in long-term cultured post-mitotic rat neurons. Aging Cell 19:e13071.

Jessen KR. (2004). Glial cells. Int J Biochem Cell Biol 36:1861–7.

Jia L, Du Y, Chu L, COAST Group, et al. (2020). Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health 5:e661–e671.

Jurr D, Wang C, Miwa S, et al. (2012). Post-mitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. Aging Cell 11:996–1004.

Kaeberlein M, Galvan V. (2019). Rapamycin and Alzheimer’s disease: time for a clinical trial? Sci Transl Med 11:eaad4289.

Kannan S, Dai H, Navath RS, et al. (2012). Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med 4:130ra46.
Kim BYS, Rutka JT, Chan WCW. (2010). Nanomedicine. N Engl J Med 363:2434–43.
Kim HJ, Seo SW, Chang JW, et al. (2015). Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase 1 clinical trial. Alzheimers Dement (N Y) 1:95–102.
Kinney JW, Bemiller SM, Murtishaw AS, et al. (2018). Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y) 4:575–90.
Kirkland JL, Tchkonia T. (2020). Senolytic drugs: from discovery to translation. J Intern Med 288:518–36.
Knopman DS, Jones DT, Greicius MD. (2021). Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement 17:696–701.
Komatsu M, Waguri S, Chiba T, et al. (2006). Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441:880–4.
Kopustinskiene DM, Jakstas V, Savickas A, Bernatoniene J. (2020). Flavonoids as anticancer agents. Nutrients 12:457.
Kou X, Chen N. (2017). Resveratrol as a natural autophagy regulator for prevention and treatment of Alzheimer's disease. Nutrients 9:927.
Krishnamurthy J, Torrice C, Ramsey MR, et al. (2004). Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114:1299–307.
Kritsilis M, V Rizou S, Koutsoudaki PN, et al. (2018). Ageing, cellular senescence and neurodegenerative disease. UMS 19:2937.
Kuhn S, Gritti L, Crooks D, Dombrowski Y. (2020). Use of functionalized liposomes loaded with conjugated 83-14 monoclonal antibody to protect β-amyloid-infiltrated neurons from systemic inflammatory microenvironment modulation. Adv Mater Cell 80:175–83.
Kuo Y-C, Lou Y-L, Rajesh R. (2020). Dual functional liposomes carrying antioxidants against tau hyperphosphorylation and apoptosis of neurons. J Drug Target 28:949–60.
Kuo Y-C, Tsao C-W. (2017). Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin. Int J Nanomed 12:2857–69.
Kuo Y-C, Tsai H-C. (2018). Rosmarinic acid- and curcumin-loaded polyacrylamide-cardiolipin-poly(lactide-co-glycolide) nanoparticles with conjugated 83:14 monoclonal antibody to protect β-amyloid-infiltrated neurons. Mater Sci Eng C Mater Biol Appl 91:445–57.
Lazar AN, Mourtah S, Youssef I, et al. (2013). Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease. Nanomedicine 9:712–21.
Lee J-H, McBrayer MK, Wolfe DM, et al. (2015). Presenilin 1 maintains lysosomal Ca(2+) homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. Cell Rep 12:1340–44.
Lee J-W, Choi HJ, Kim E-J, et al. (2020). Fisetin induces apoptosis in uterine leiomyomas through multiple pathways. Sci Rep 10:7993.
Lei T, Yang Z, Xia X, et al. (2021). A nanocleaner specifically penetrates the blood-brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer's disease. Acta Pharmac Sin B 11:4032–44.
Li Q, Gao Y, Dang C, et al. (2020). Inhibition of double-strand DNA-sensing cGAS ameliorates brain injury after ischemic stroke. EBioMed Mol Med 12a11002.
Li W, Guo Q, Zhao H, et al. (2012). Novel dual-control pol y(N-isopropylacrylamide-co-chlorophyllin) nanogels for improving drug release. Nanomedicine (Lond) 7:383–92.
Li W, He Y, Zhang R, et al. (2019). The curcumin analog EF24 is a novel senolytic agent. Aging (Albany NY) 11:771–82.
Limbad C, On TR, Almirah F, et al. (2020). Astrocyte senescence promotes glutamate toxicity in cortical neurons. PLoS One 15:e0227887.
Lipinski MM, Zheng B, Lu T, et al. (2010). Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc Natl Acad Sci U S A 107:14164–9.
Liu P, Zhang T, Chen Q, et al. (2021). Biomimetic dendrimer-peptide conjugates for early multi-target therapy of Alzheimer's disease by inflammatory microenvironment modulation. Adv Mater 33:e2100746.
Liu Q, Li Y, Jiang W, et al. (2016). Inhibition of HSP90 promotes neural stem cell survival from oxidative stress through attenuating NF-κB/p65 activation. Oxid Med Cell Longev 2016:3507290.
Liu Y-C, Gao X-X, Chen L, You X-Q. (2017). Rapamycin suppresses AB25-35- or LPS-induced neuronal inflammation via modulation of NF-κB signaling. Neuroscience 355:188–99.
Livingston G, Huntley J, Sommerlad A, et al. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396:413–46.
Lopes-Pacienca S, Saint-Germain E, Rowell M-C, et al. (2019). The senescence-associated secretory phenotype and its regulation. Cytokine 115:17–22.
Lu Y, Guo Z, Zhang Y, et al. (2019). Microenvironment remodeling micelles for Alzheimer's disease therapy by early modulation of activated microglia. Adv Sci (Weinh) 6:1801586.
Mathew A, Fukuda T, Nagaoka Y, et al. (2012). Curcumin loaded-PLGA nanoparticles conjugated with Tett-1 peptide for potential use in Alzheimer's disease. PLoS One 7:e32616.
McGeer PL, McGeer E, Rogers J, Sibley J. (1990). Anti-inflammatory drugs and Alzheimer disease. Lancet 335:1037.
McGeer PL, Rogers J, McGeer EG. (2016). Inflammation, anti-inflammatory agents, and Alzheimer's disease: the last 22 years. J Alzheimers Dis 54:853–7.
McGeer PL, Schulzer M, McGeer EG. (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47:425–32.
McHugh D, Gil J. (2018). Senescence and aging: causes, consequences, and therapeutic avenues. J Cell Biol 217:65–77.
Meng F, Asghar S, Gao S, et al. (2015). A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer's disease. Colloids Surf B Biointerfaces 134:88–97.
Mhatre SD, Tsai CA, Rubin AJ, et al. (2015). Microglial malfunction: the third rail in the development of Alzheimer's disease. Trends Neurosci 38:621–36.
Mohamad Anuar NN, Nor Hisam NS, Liew SL, Ugusman A. (2020). Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent. Front Pharmacol 11:564108.
Moiseeva O, Deschênes-Simard X, St-Germain E, et al. (2013). Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell 12:489–98.
Mourtah S, Lazar AN, Markoutsa E, et al. (2014). Multifunctional nanoliposomes with curcumin-avid lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur J Med Chem 80:175–83.
Mulkir RJ, Mönkönen J, Juvenon RO, et al. (2010). ApoE mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharmacol 7:815–25.
Musí N, Valentine JM, Sickora KR, et al. (2018). Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell 17:e12840.
Nalivaeva NN, Turner AJ. (2019). Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy. Br J Pharmacol 176:3447–63.
Nayak D, Roth TL, McGavern DB. (2013). Microglia development and therapeutic avenues. Annu Rev Immunol 32:367–402.
Neves AR, Queiroz JF, Reis S. (2014). Oligodendrocytes in AD: functions and therapeutic avenues. J Cell Physiol 229:1965–74.
Nguyen PM, Chang NC, Gao X, et al. (2019). Inflammation, anti-inflammatory agents, and Alzheimer's disease: the last 22 years. J Alzheimers Dis 54:853–7.
Neves AR, Queiroz JF, Reis S. (2014). Oligodendrocytes in AD: functions and therapeutic avenues. J Cell Physiol 229:1965–74.
Ott C, König J, Höhn A, et al. (2016). Macroautophagy is impaired in old murine brain tissue as well as in senescent human fibroblasts. Redox Biol 10:266–73.

Palma S, Maity AR, Singh BK, et al. (2016). Inhibition of amyloid fibril growth and dissolution of amyloid fibrils by curcumin-gold nanoparticles. Chemistry 20:6184–91.

Papissov MI, Belov VV, Gannon KS. (2013). Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS. Mol Pharm 10:1522–32.

Park D, Yang Y-H, Bae DK, et al. (2013). Improvement of cognitive function and physical activity of aging mice by human neural stem cells over-expressing choline acetyltransferase. Neurobiol Aging 34:2639–46.

Pickford F, Masliah E, Britschgi M, et al. (2008). The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 118:2190–9.

Picone P, Ditta LA, Sabatino MA, et al. (2016). Ionizing radiation-engineered nanogels as insulin nanocarriers for the development of a new strategy for the treatment of Alzheimer’s disease. Biomaterials 80:179–94.

Piskovatska V, Storey KB, Vasierman AM, Lushchak O. (2020). The use of metformin to increase the human healthspan. Adv Exp Med Biol 1260:319–32.

Prata LGPL, Ovsyannikova IG, Tchkonia T, Kirkland JL. (2018). Senescent cell clearance by the immune system: emerging therapeutic opportunities. Semin Immunol 40:101275.

Price JF, Stewart MC, Deary IJ, AAA Trialists, et al. (2008). Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ 337:a1198.

Prins ND, Scheltens P. (2015). White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol 11:157–65.

Ries M, Sastre M. (2016). Mechanisms of Aβ clearance and degradation by glial cells. Front Aging Neurosci 8:160.

Ross C, Taylor M, Fullwood N, Allsop D. (2016). Liposome delivery systems for the treatment of Alzheimer’s disease. Int J Nanomed 13:8507–22.

Ries M, Sastre M. (2016). The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. EBiomedicine 6:42–9.

Shah S, Rangaraj N, Laxmikeshav K, Sampathi S. (2020). Nanogels as drug carriers - Introduction, chemical aspects, release mechanisms and potential applications. Int J Pharm 581:119268.

Shengupta U, Nilson AN, Kayed R. (2016). Induction of pluripotent stem cells by inhibiting inositol monophosphatase. J Cell Biol 170:1101–11.

Sengupta U, Nilson AN, Kayed R. (2016). The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. EBiomedicine 6:42–9.

Shah S, Rangaraj N, Laxmikeshav K, Sampathi S. (2020). Nanogels as drug carriers - Introduction, chemical aspects, release mechanisms and potential applications. Int J Pharm 581:119268.

Shehzad A, Lee YS. (2013). Molecular mechanisms of curcumin action: signal transduction. Biofactors 39:27–36.

Shok BA, Manz DH, Peters JI, et al. (2012). Spatiotemporal changes to the subventricular zone stem cell pool through aging. J Neurosci 32:9647–56.

Sierra A, Gottfried-Blackmore AC, McEwen BS, Bulloch K. (2007). Microglia derived from aging mice exhibit an altered inflammatory profile. Glia 55:412–24.

Sochocka M, Donskow-Łysoniewska K, Diniz BS, et al. (2019). The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer’s disease - a critical review. Mol Neurobiol 56:1841–51.

Soenen SJ, Rivera-Gil P, Montenegro JM, et al. (2011). Cellular toxicity of inorganic nanoparticles: common aspects and guidelines for improved nanotoxicity evaluation. Nano Today 6:446–65.

Son SM, Shin H-J, Byun J, et al. (2016). Metformin facilitates amyloid-β generation by β- and γ-secretases via autophagy activation. J Alzheimers Dis 51:1197–208.

Song S, Lam EW-F, Tchkonia T, et al. (2020). Senescent cells: emerging targets for human aging and age-related diseases. Trends Biochem Sci 45:578–92.

Srinivasan K, Friedman BA, Etxeberria A, et al. (2020). Alzheimer’s patient microglia exhibit enhanced aging and unique transcriptional activation. Cell Rep 31:107843.

Steele JW, Gandy S. (2013). Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy 9:617–8.

Su X, Song H, Niu F, et al. (2015). Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance. Nanomedicine (Lond) 10:2033–50.

Sun Y, Coppé J-P, Lam EW-F. (2018). Cellular senescence: the sought or the unwanted? Trends Mol Med 24:87–81.

Sweeney MD, Sagare AP, Zlokovic BV. (2018). Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14:133–50.

Takahashi K, Yamanaka S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–76.

Twari SK, Agarwal S, Seth B, et al. (2014). Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/β-catenin pathway. ACS Nano 8:76–83.

Triana-Martínez F, Picallos-Rabina P, Da Silva-Alvarez S, et al. (2019). Identification and characterization of Cardiac Glycosides as senolytic compounds. Nat Commun 10:4731.

Vaz M, Silvestre S. (2020). Alzheimer’s disease: recent treatment strategies. Eur J Pharmacol 887:173554.

Verkhratsky A, Niedergaard M. (2018). Physiology of the astroglia. Physiol Rev 98:239–389.

Vingdeptsy V, Chandakkar P, Zhao H, et al. (2011). Novel synthetic small-molecule-activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. Faseb J 25:219–31.

Wang F, Ren S-Y, Chen J-F, et al. (2020). Myelogen degeneration and diminished myelin renewal contribute to age-related deficits in memory. Nat Neurosci 23:481–6.

Wang Y, Chang J, Liu X, et al. (2016). Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. Aging (Albany NY) 8:2915–26.

Wang Y, Pang J, Wang Q, et al. (2021). Delivering antisense oligonucleotides across the brain-blood barrier by tumor cell-derived small apoptotic bodies. Adv Sci (Weinh) 8:2004929.

Watanabe Y, Taguchi K, Tanaka M. (2020). Ubiquitin, autophagy and neurodegenerative diseases. Cells 9:2022.

Wong KH, Riaz MK, Xie Y, et al. (2019). Review of current strategies for delivering Alzheimer’s disease drugs across the blood-brain barrier. UJMS 20:381.

Xie XP, Laks DR, Sun D, et al. (2020). High-resolution mouse subventricular zone stem-cell niche transcriptome reveals features of lineage, anatomy, and aging, Proc Natl Acad Sci U S A 117:3448–58.

Yamazaki Y, Baker DJ, Tachibana M, et al. (2016). Vascular cell senescence contributes to blood-brain barrier breakdown. Stroke 47:1068–77.

Yamazaki Y, Kanekiyo T. (2017). Blood-brain barrier dysfunction and the pathogenesis of Alzheimer’s disease. UJMS 18:1965.

Yeh FL, Wang Y, Tom I, et al. (2016). TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 91:328–40.

Yu H-M, Zhao Y-M, Luo X-G, et al. (2012). Repeated lipopolysaccharide stimulation induces cellular senescence in BV2 cells. Neuroimmunomodulation 19:131–6.

Zandi PP, Anthony JC, Hayden KM, Cache County Study Investigators, et al. (2002). Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County study. Neurology 59:880–6.

Zhang P, Kishimoto Y, Grammatikakis I, et al. (2021). Delivery of myelin-targeting gene therapy bolus: the leptomeningeal route for macromolecule and particle delivery to CNS. Mol Pharm 18:2004929.

Zlokovic BV. (2002). Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County study. Neurology 59:880–6.